Business
Aussie cannabis players blaze a trail in Europe – The Australian Financial Review
ASX-listed MGC Pharma has floated in London while Little Green Pharma has placed $22 million of shares, as the high-potential European market beckons.
Australia is so set up to have a really great crack at being the dominant player in Europe, said LGP founder and CEO Fleta Solomon.
She said the Australian advantage was that the Therapeutic Goods Associations good manufacturing practice (GMP) standards were recognised as complying with the European Unions high bar, whereas producers in other countries had to negotiate EU clearance.
The biggest companies in the world dont have EU GMP. Thats what is so exciting for us as Australian players. Our GMP…
-
General23 hours agoQantas terminal at Melbourne Airport evacuated and flights delayed due to fire
-
General20 hours agoHome of Andrii Yermak, Zelenskyy’s chief of staff, raided by anti-corruption unit
-
General9 hours agoProtecting victims of explicit AI content online
-
General17 hours agoFamily ties loom large in premier’s by-election test